SS-31 (elamipretide): mechanism, evidence and research limits

SS-31 is elamipretide (also called MTP-131 and Bendavia), a synthetic aromatic-cationic tetrapeptide—not a hormone, blend, topical cosmetic ingredient or small molecule. Its sequence is H-D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH2 (RXKF); it is designed to associate with cardiolipin in the inner mitochondrial membrane.

SS-31, or elamipretide, is a real four-amino-acid synthetic peptide with substantial laboratory and clinical research. Its clearest molecular observation is interaction with cardiolipin, a mitochondrial inner-membrane phospholipid. Animal and biochemical results are not proof of human benefit. In the pivotal 218-person primary mitochondrial myopathy trial, elamipretide did not improve either prespecified primary outcome at 24 weeks. Its 2025 US accelerated approval is instead limited to improvement of muscle strength in genetically confirmed Barth syndrome for patients weighing at least 30 kg, based on an intermediate strength endpoint and subject to confirmatory evidence. No supplier vial should be treated as interchangeable with the FDA-approved prescription product, and Australian approval or a general self-administration regimen should not be inferred.

SS-31 is the development name for elamipretide, a synthetic tetrapeptide. The sequence includes D-arginine, 2,6-dimethyltyrosine, lysine and phenylalaninamide; databases also list MTP-131 and Bendavia as names for the same active moiety. That makes it a peptide in the ordinary chemical sense, not NAD+, a conventional small-molecule medicine, or a naturally occurring hormone. [1]

The term “SS-31” alone does not identify a regulated finished medicine. In the United States, the approved product is FORZINITY (elamipretide), a defined prescription injection with a particular formulation, indication and labelling. A powder or liquid advertised online as “SS-31”, including one marked “research use only”, is not thereby the same product or evidence base. [7] [9]

Cardiolipin is a phospholipid concentrated in the inner mitochondrial membrane, where membrane architecture and respiratory machinery depend on it. In a biochemical and cell/animal study, a fluorescent SS-31 analogue bound cardiolipin with reported micromolar affinity; the authors also found that the SS-31–cardiolipin complex inhibited cardiolipin-associated cytochrome-c peroxidase activity in their experimental systems. These are mechanistic observations, not demonstrations that the peptide restores mitochondrial disease in people. [2]

A later rat cardiac ischaemia–reperfusion study supported membrane interaction but usefully narrowed the claim. Elamipretide partly restored cristae-network connectivity and preserved aspects of mitochondrial structure–function, yet acute treatment did not prevent the measured fall in total cardiolipin after ischaemia–reperfusion. The authors also noted that their biomimetic membrane system lacked proteins. “Protects cardiolipin” is therefore too broad a description of this evidence. [3]

The influential 2013 paper was not a human efficacy trial. It combined lipid and mitochondrial experiments with a rat renal-ischaemia model. Rats pretreated with SS-31 had preserved mitochondrial cristae and less swelling after renal ischaemia; faster ATP recovery on reperfusion was accompanied by faster restoration of tubular-cell features and less renal dysfunction in that model. The result is relevant to an experimentally induced rat kidney injury, not a validated treatment effect for chronic fatigue, ageing, athletic performance or every mitochondrial disorder. [2]

The 2020 cardiac study used rats subjected to cardiac ischaemia–reperfusion and complementary membrane models. It observed less fragmentation of cristae networks with elamipretide, while also finding no acute protection against the decline in cardiolipin content. Species, induced injury, timing and laboratory endpoints all limit direct extrapolation from these models to human diagnoses or outcomes. [3]

An early phase I/II trial enrolled 36 people with genetically confirmed primary mitochondrial myopathy across three 12-person, randomised, double-blind cohorts. It tested five days of intravenous treatment at ascending doses. At the highest dose, a covariate-adjusted analysis found a larger day-5 change in six-minute walk distance than placebo, but other efficacy measures and biomarkers did not significantly differ. The small, short study was designed partly for pharmacokinetics; it was an efficacy signal to test, not a durable treatment protocol. [4]

The subsequent MMPOWER-3 phase 3 trial is more decisive for primary mitochondrial myopathy. It randomised 218 adults 1:1 to elamipretide or placebo for 24 weeks. It missed both primary endpoints: the between-group difference in six-minute walk distance was −3.2 m (95% CI −18.7 to 12.3; p=0.69), and the total fatigue-score difference was not significant. The study therefore does not establish elamipretide as effective for primary mitochondrial myopathy overall. [5]

A post-hoc subgroup of participants with nuclear-DNA defects had a 25.2-metre between-group difference in six-minute walk change, while the mitochondrial-DNA subgroup did not benefit versus placebo. Because this was post-hoc within a trial that failed its primary endpoints, it is a hypothesis for future genotype-defined studies rather than a basis for selecting or dosing treatment. The investigators also identified heterogeneous disease, effort-dependent outcomes and limited biomarkers as trial-design challenges. [5]

Barth syndrome is a rare X-linked condition caused by pathogenic TAZ variants that disrupt cardiolipin remodelling. This biology makes it a more specific test case for a cardiolipin-binding candidate than the broad category of mitochondrial symptoms. In TAZPOWER, 12 males aged 12–35 years with genetically confirmed Barth syndrome completed a randomised, double-blind, placebo-controlled crossover phase. Neither primary endpoint—six-minute walk distance or the Barth syndrome symptom-assessment fatigue score—was superior to placebo after 12 weeks. [6]

In the study’s later open-label extension, eight participants assessed at week 36 had improved six-minute walk and symptom scores versus baseline, but the lack of a concurrent placebo group means placebo effects, learning effects and time-related variation cannot be excluded. Injection-site reactions were common and two participants discontinued the extension. These limitations matter because the apparent later gains should not be read as the same evidentiary strength as a positive controlled trial. [6]

On 19 September 2025, the FDA granted accelerated approval to FORZINITY for improving muscle strength in adults and paediatric patients with Barth syndrome who weigh at least 30 kg. The FDA states that approval was based on knee-extensor strength, an intermediate endpoint reasonably likely to predict benefit, and requires a confirmatory randomised, double-blind, placebo-controlled trial. It is not approval for primary mitochondrial myopathy, heart disease, anti-ageing or healthy-person performance. [7] [8]

In MMPOWER-3, treatment-emergent adverse events were reported by 98.2% of elamipretide-treated participants versus 76.1% of placebo participants. The commonly reported elamipretide events were injection-site reactions, including redness, itch, pain, swelling, bruising, hives and nodules; 7.3% discontinued because of adverse events versus 1.8% on placebo. Serious events were uncommon and were not considered treatment-related in that study, but a 24-week trial cannot settle long-term safety across different uses. [5]

The US label for the approved formulation warns about serious hypersensitivity reactions and its benzyl-alcohol-containing product is not approved for neonates. It lists injection-site reactions as the most common adverse reactions. These label statements apply to FORZINITY as supplied and studied; they do not validate the purity, sterility, excipients, concentration or safety of a research-supplier vial. [7]

Australia’s ARTG is the TGA reference database for therapeutic goods that can be supplied in Australia; unless an exemption applies, therapeutic goods not in the ARTG cannot be supplied. This review confirmed US FDA approval but did not identify an Australian ARTG entry or Australian product information for elamipretide. That is a reason to check the current ARTG directly, not a reason to treat an overseas product, clinic claim or supplier listing as Australian approval. [8] [10]

The TGA says unapproved peptide products have not been evaluated by it for safety, quality or effectiveness and highlights risks including uncertain ingredients, sterility, contamination and injection injury. It also states that a “research use only” disclaimer does not change regulatory status or make supply lawful. This general guidance is particularly relevant when a product is offered under a research code rather than as a registered, labelled medicine. [9]

Keep three evidence layers separate. First, biochemical binding and rodent injury experiments can explain why elamipretide was developed. Second, controlled human trials test whether that mechanism produces patient-important benefit in a defined disease. Third, a regulator may approve a particular manufactured formulation for one indication. A positive result in the first layer does not establish the second, and a US approval in Barth syndrome does not transfer to unrelated conditions or countries. [2] [3] [5] [7]

Do not convert study regimens into general dosing instructions. The early mitochondrial-myopathy study was a five-day monitored intravenous experiment, whereas the approved US Barth-syndrome product has its own labelled prescription context. There is no validated universal SS-31 schedule, dilution, route, storage rule or combined “stack” protocol for supplier vials. Combining it with other substances also creates a new, untested exposure rather than reproducing a single-agent trial. [4] [7] [9]

Is SS-31 actually a peptide?

Yes. SS-31 is elamipretide, a synthetic tetrapeptide (four amino-acid residues), not a small molecule or hormone. [1]

Is SS-31 approved as a medicine?

It has a narrow US accelerated approval as FORZINITY to improve muscle strength in Barth syndrome in people weighing at least 30 kg. Continued US approval depends on confirmatory clinical benefit. That does not establish approval for other diseases or in Australia. [7] [8] [10]

Does it work for primary mitochondrial myopathy?

The pivotal 24-week, 218-participant MMPOWER-3 trial did not improve its prespecified six-minute-walk or fatigue primary outcomes versus placebo. A post-hoc nuclear-DNA subgroup result needs confirmation and is not a general efficacy finding. [5]

Can an online “research” vial be used as though it were the approved product?

No. A supplier vial is not demonstrated to be equivalent to the defined FDA-approved formulation. The TGA warns that “research use only” does not alter regulatory obligations and that unapproved injectable peptides raise quality and safety concerns. [7] [9]

Mechanistic evidence comes largely from biochemical systems and induced rodent ischaemia–reperfusion models; it does not establish effects in humans with chronic or unrelated conditions.

The early primary-mitochondrial-myopathy efficacy signal came from 36 participants after five days, whereas the larger 218-participant phase 3 study did not meet either coprimary endpoint.

The Barth syndrome controlled trial had 12 participants and did not meet its primary endpoints; later apparent gains were open-label, so they cannot exclude placebo and learning effects.

US accelerated approval is formulation- and indication-specific and depends on confirmatory evidence. Australian status should be checked in the ARTG rather than inferred from US regulatory material or online suppliers.

No general SS-31 administration, dilution, storage or combination protocol is supported by these sources; research-supplier product quality and content cannot be assumed.

1. [1] Elamipretide. Curated substance and structural record
2. [2] The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. Biochemical lipid and mitochondrial experiments, feline kidney-cell localisation work, and rat renal ischaemia–reperfusion model
3. [3] The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats. Rat cardiac ischaemia–reperfusion, mitochondrial ultrastructure/functional analyses and biomimetic membrane experiments
4. [4] Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Phase I/II multicentre randomised, double-blind, placebo-controlled multiple-ascending-dose trial; 36 genetically confirmed primary mitochondrial myopathy participants
5. [5] Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Phase 3 multicentre randomised, double-blind, placebo-controlled parallel-group trial; 218 participants over 24 weeks
6. [6] A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Randomised, double-blind, placebo-controlled crossover trial in 12 people with Barth syndrome followed by open-label extension
7. [7] FORZINITY (elamipretide) injection: US Prescribing Information. FDA-approved prescribing information and clinical-study summary
8. [8] FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. FDA approval announcement
9. [9] Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. TGA safety advisory and regulatory guidance
10. [10] Searching the Australian Register of Therapeutic Goods (ARTG). TGA ARTG database guidance